Overview | Day 1 | Day 2 | Download Brochure


• New Approaches for RNAi Delivery
• Exploring Diverse Therapeutic Indications
• Addressing Safety and Manufacturing Concerns

 

DISTINGUISHED FACULTY

 

Evgenia Alpert, M.D., Ph.D., Quark Pharmaceuticals Inc.

 

Mark Behlke, M.D., Ph.D., Integrated DNA Technologies

 

Johannes Freuhauf, M.D., Ph.D., Cequent Pharmaceuticals Inc.

 

Todd Kreutzian, Agilent Technologies

 

Robert J. Lee, Ph.D., Ohio State University

 

Zdravka Medarova, Ph.D., Massachusetts General Hospital

 

Ian McLachlan, Ph.D., Protiva Biotherapeutics Inc.

 

Pieter Peeters, Ph.D., Johnson & Johnson Pharmaceutical Research and Development

 

Dmitry Samarsky Ph.D., RXi Pharmaceuticals Corp.

 

Ansgar Santel, Ph.D., Silence Therapeutics AG

 

Mohan Sapru, Ph.D., Northwestern University


Thomas Singer, D.A.B.T., F. Hoffmann-La Roche AG

 

Eric Tien, Ph.D., Pfizer

 

Michael Templin, Ph.D., D.A.B.T., Nastech Pharmaceutical Co.

 

Jian Wu, M.D., Ph.D., University of California – Davis Medical Center

 

Lei Yu, M.D., Ph.D., Nitto Denko Technical Corp.

 

John Zaia, M.D., Beckman Research Institute